Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | IDUA | P35475 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707861 | 1.00 | CYP2D6 (0.41) | CYP2D6IDUAALOX15KDM4EEGFR | |
| SCHEMBL16105890 | 1.00 | CYP2D6 (0.41) | CYP2D6IDUAALOX15KDM4EEGFR | |
| SCHEMBL2707859 | 1.00 | CYP2D6 (0.41) | CYP2D6IDUAALOX15KDM4EEGFR | |
| SCHEMBL5735389 | 1.00 | CYP2D6 (0.41) | CYP2D6IDUAALOX15KDM4EEGFR | |
| SCHEMBL28475955 | 1.00 | CYP2D6 (0.41) | CYP2D6IDUAALOX15KDM4EEGFR | |
| SCHEMBL890247 | 0.83 | CYP2D6 (0.37) | CYP2D6 | |
| SCHEMBL13327023 | 0.78 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL12980346 | 0.78 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL20693077 | 0.78 | CYP2D6 (0.51) | CYP2D6EGFR | |
| SCHEMBL13327015 | 0.78 | CYP2D6 (0.35) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-111808040-B | Synthesis method of multi-configuration 2-oxo-oxazolidine-4-carboxylic acid compounds | 苏州爱玛特生物科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| CN-111808040-A | Synthesis method of multi-configuration 2-oxo-oxazolidine-4-carboxylic acid compounds | 苏州爱玛特生物科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| WO-2020083336-A1 | 1,3,4-OXADIAZOLE-2-CYCLOBUTYL COMPOUNDS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2020-04-30 | — | — | WO | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-5356918-A | Oxazolidinone compounds and method of using the same as a vasodilator | SANKYO COMPANY, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| US-5298516-A | Treatment of cardiovascular disorders, angina | SANKYO COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2D6 1658/4885IDUA 4578/4885ALOX15 3166/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | CYP2D6 4808/4885IDUA 4620/4885ALOX15 4462/4885 |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | CYP2D6 2297/4885IDUA 4721/4885ALOX15 1757/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP2D6 1861/4885IDUA 3237/4885ALOX15 2436/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | CYP2D6 655/4885IDUA 4066/4885ALOX15 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.